**NeuroPace, Inc. (NPCE) Reports Q2 2026 Earnings**
NeuroPace, Inc. announced a second-quarter 2026 loss per share of $0.18, narrowing from a loss of $0.30 in the same quarter last year. The report, released on [insert date], showed revenues of $22.8 million, reflecting a 17.1% year-over-year increase, and surpassed the Zacks Consensus Estimate by 0.6%. The company attributes revenue growth largely to its RNS System, with revenues reaching $22.5 million, up 21.3% from the previous year.
**Financial Highlights and Outlook**
NeuroPace ended the quarter with $51.7 million in cash, down from $53.9 million at the end of Q1 2026. Management has raised its full-year revenue guidance for 2026 to between $99.5 million and $101.5 million, reflecting anticipated service revenue growth. The company also indicated an adjusted operating loss narrowing to $2.8 million from $5 million in the prior year’s quarter.
**Market Reaction and Future Developments**
Despite strong quarterly performance, shares of NeuroPace fell approximately 2.3% in after-market trading following the earnings release. The company has set ambitious growth targets for its core RNS business, aiming for over 20% growth through increased prescriber expansion and innovative AI developments in clinical decision tools.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
